NFL BIOSCIENCES: AUTHORIZATION OF CLINICAL TRIAL TO DEMONSTRATE THE COMPLEMENTARITY OF NFL-101 WITH OTHER SMOKING CESSATION TREATMENTS – 11/08/2022 at 18:00
NFL BIOSCIENCES (Euronext Growth Paris – FR0014003XT0 – ALNFL), a biopharmaceutical company developing botanical drugs for the treatment of dependence and